Hematopoiesis News Volume 4.36 | Sep 17 2013

    0
    20
    Hematopoiesis News 4.36 September 17, 2013

    Hematopoiesis News

         In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  Hematopoiesis News on Twitter

     
    TOP STORY
    FLVCR Is Necessary for Erythroid Maturation, May Contribute to Platelet Maturation, but Is Dispensable for Normal Hematopoietic Stem Cell Function
    To explore a possible role for FLVCR in hematopoietic stem cell function, scientists performed serial, competitive repopulation transplant experiments using FLVCR-deleted and control bone marrow cells, along with wild-type competitor cells. [Blood] Abstract
    [Free On-Demand Webinar] Potential Applications of ALDH+ Cells in Regenerative Medicine - Watch Now.

     
    PUBLICATIONS (Ranked by impact factor of the journal)
    LABORATORY RESEARCH

    DNA Methylation of Runx1 Regulatory Regions Correlates with Transition from Primitive to Definitive Hematopoietic Potential In Vitro and In Vivo
    The authors investigated DNA methylation of known Runx1 cis-elements at stages of hematopoietic development in vivo, and during differentiation of murine embryonic stem cells in vitro. They found at the distal promoter, loss of methylation correlated with the primitive to definitive transition in vivo. [Blood] Abstract

    Growth Factor Independent-1 Maintains Notch1-Dependent Transcriptional Programming of Lymphoid Precursors
    Scientists showed that immature hematopoietic cells require Growth factor independent 1 (Gfi1) to competently integrate Notch-activated signaling. Notch1 activation coupled with Gfi1 deficiency early in T-lineage specification leads to a dramatic loss of T-cells, whereas activation in later stages leaves development unaffected. [PLoS Genet] Full Article

    Expression of Podocalyxin Separates the Hematopoietic and Vascular Potentials of Mouse ES Cell-Derived Mesoderm
    Researchers report that surface expression of Podocalyxin (Podxl), a member of the CD34 family of sialomucins, can be used to subdivide the Flk1+ cells in differentiating embryoid bodies at day 4.75 into populations that develop into distinct mesodermal lineages. Definitive hematopoietic potential was restricted to the Flk1+Podxl+ population, while the Flk1-negative Podxl+ population displayed only primitive erythroid potential. [Stem Cells] Abstract

    Loss of Quiescence and Impaired Function of CD34+/CD38low Cells One Year Following Autologous Stem Cell Transplantation
    Bone marrow primitive progenitor cells were examined one year following autologous stem cell transplantation and compared with normal bone marrow and mobilized peripheral blood stem cells. Post-transplantation bone marrow contained a significant lower percentage of quiescent cells in the CD34+/CD38low fraction compared to normal bone marrow. [Haematologica] Abstract | Full Article

    Characterization of Regulatory Dendritic Cells that Mitigate Acute Graft-versus-Host Disease in Older Mice Following Allogeneic Bone Marrow Transplantation
    Prophylaxis with syngeneic regulatory dendritic cells (DCreg) in young bone marrow transplanted (BMT) mice has been shown to decrease graft-versus-host disease-associated mortality. To evaluate this approach in older BMT recipients, young (3-4 months) and older (14-18 months) DCreg were generated using GM-CSF, IL-10, and TGFβ. [PLoS One] Full Article

    Drosophila E-Cadherin Functions in Hematopoietic Progenitors to Maintain Multipotency and Block Differentiation
    Scientists showed that E-cadherin is an important regulator of prohemocyte fate choice, maintaining prohemocyte multipotency and blocking differentiation. These functions are reminiscent of the role of E-cadherin in mammalian embryonic stem cells. [PLoS One] Full Article

    GSK-3β Inhibition Preserves Naïve T Cell Phenotype in Bone Marrow Reconstituted Mice
    Investigators demonstrated that GSK-3β inhibitor, 6-bromoindirubin 3′-oxime, activates Wingless/β-catenin signaling, elevates the proportion of naïve T cells and delays T cell differentiation during homeostatic T cell expansion in lymphodepleted mice transplanted with human hematopoietic stem cells. [Exp Hematol] Abstract

    Active RHOA Favors Retention of Human Hematopoietic Stem/Progenitor Cells in Their Niche
    By utilizing constitutively active and dominant negative RHOA, scientists showed that RHOA negatively regulates both in vitro and in vivo migration and dominant negative RHOA significantly increased the migration potential of human hematopoietic stem/progenitor cells. [J Biomed Sci] Full Article

    CLINICAL RESEARCH

    CMV Serostatus Has Still an Important Prognostic Impact in De Novo Acute Leukemia Patients after Allogeneic Stem Cell Transplantation: A Report from the Acute Leukemia Working Party of EBMT
    Investigators analyzed the prognostic impact of donor and recipient cytomegalovirus (CMV) serostatus in 16628 de novo acute leukemia patients after allogeneic stem cell transplantation. In comparison to CMV-seronegative recipients allografted from a CMV-seronegative donor, cases with CMV seropositivity of the donor and/or the recipient showed a significantly decreased 2-year leukemia-free survival and overall survival, and increased non-relapse mortality. [Blood] Abstract

    An Intermediate Alemtuzumab Schedule Reduces the Incidence of Mixed Chimerism Following Reduced Intensity Conditioning Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistiocytosis
    Researchers hypothesized that an intermediate alemtuzumab schedule would reduce mixed chimerism and maintain a low incidence of acute GVHD. Twenty-four consecutive transplants were performed in patients with hemophagocytic lymphohistiocytosis and related disorders using a novel intermediate alemtuzumab schedule of 1mg/kg beginning on day-14. [Biol Blood Marrow Transpl] Abstract

    Register for Live Webinar: Customizing the Hematopoietic CFC Assay for Drug Development

     
    REVIEWS
    Hematopoietic Stem Cell Niches: New Insights Inspire New Questions
    With particular emphasis on cell type-specific deletion of SCL and CXCL12, the authors focus on unresolved issues on hematopoietic stem cell (HSC) niches, framed around some very recent advances and novel discoveries on the extrinsic regulation of HSC maintenance. [EMBO J] Full Article

    Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

    Save 20% Off the Standard Rate to Attend IBC’s Cell Therapy Bioprocessing Event: Mention Priority Code B13188CONNEXON when you register.

     
    SCIENCE NEWS
    Chimerix Presents Brincidofovir (CMX001) Adenovirus Phase II Results
    Chimerix, Inc. announced the results from its exploratory Phase II Study 202 evaluating brincidofovir (CMX001) in hematopoietic cell transplant recipients with early adenovirus infection. [Press release from Chimerix, Inc. discussing research presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Denver] Press Release

    From our sponsor:
    View immunology lectures, protocols and other resources on the Human Immunology Portal.

     
    INDUSTRY NEWS
    Weill Cornell Medical College Receives $100 Million Gift from Joan and Sanford I. Weill and the Weill Family Foundation to Launch New Capital Campaign
    Weill Cornell Medical College announced that it has received a $100 million gift from longtime benefactors Joan and Sanford I. Weill and the Weill Family Foundation to launch the Medical College’s $300 million Driving Discoveries, Changing Lives campaign dedicated to using the most advanced scientific approaches to rapidly translate research breakthroughs into innovative treatments and therapies for patients. [Weill Cornell Medical College] Press Release

    Sernova and Medicyte to Collaborate on Cell-Based Therapy to Treat Hemophilia
    Sernova Corp. and Medicyte GmbH announced that the companies have entered into a Material Transfer Agreement to jointly evaluate the use of Medicyte’s upcyte® cells in Sernova’s Cell Pouch™ for the treatment of patients with hemophilia A. [Sernova Corp.] Press Release

     
    POLICY NEWS
    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

     
    EVENTS
    NEW American Society for Cell Biology
    December 14-18, 2013
    New Orleans, United States

    Visit our events page to see a complete list of events in the hematopoiesis research community.

     
    JOB OPPORTUNITIES
    NEW Research Associate – Leukemia & Stem Cell Biology (King’s College London)

    Postdoctoral Fellow – Mechanisms that Regulate Stem Cell Self-Renewal Using Mouse Blood-Forming Stem Cells (Columbia University)

    Postdoctoral Opportunity in Hematopoietic Stem Cells (Albert Einstein College of Medicine [AECOM])

    Postdoctoral Researcher – Hematopoietic and Malignant Stem Cells (Istanbul University Institute of Experimental Medicine)

    Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

    Postdoctoral Position – Hematopoietic Stem Cells (St. Jude Children’s Research Hospital)

    Postdoctoral Appointee – Cell Cycle Regulation in Tumor Stem Cells (Rutgers University, Rutgers Cancer Institute of New Jersey)


    Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

     

    Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

    Comments or Suggestions? Email info@connexoncreative.com with your feedback.

    Learn more about Hematopoiesis News: Archives | Events | Contact Us